Dr. Marat Seitkali

Dr. Marat Seitkali is a consultant medical oncologist at the National Oncology Center in Almaty — Kazakhstan's largest city and commercial capital, home to the country's most advanced oncology institution. Kazakhstan carries a significant cancer burden, with lung, colorectal, and gastric cancers among the leading malignancies, and the National Oncology Center in Almaty manages the country's most complex oncology cases.

With 16 years of oncology practice, Dr. Seitkali specializes in thoracic and gastrointestinal oncology, applying molecular profiling to guide systemic therapy decisions. Kazakhstan has been expanding access to targeted therapies and immunotherapy through government health programs, and Dr. Seitkali is an active advocate for ensuring Kazakhstani cancer patients receive access to the most effective modern treatments.

For lung cancer, he applies EGFR, ALK, ROS1, KRAS, and PD-L1 testing to guide treatment selection — prescribing targeted therapies where applicable and immunotherapy combinations for high PD-L1 expressors. For gastrointestinal cancers, he manages colorectal and gastric cancer with contemporary cytotoxic and biologic regimens.

Dr. Seitkali trained in France through a Kazakhstan-France academic exchange and holds ESMO certification. He communicates in Kazakh, Russian, and English.

Dr. Seitkali obtained his MD from the Kazakh National Medical University and completed Oncology residency at the National Oncology Center Almaty. He undertook a Medical Oncology Fellowship at the Institut de Cancérologie de l'Ouest in Nantes, France, through a Kazakhstan-France academic exchange program. He holds a PhD in Oncology from Kazakh National Medical University and the ESMO certification. He maintains active ESMO membership and participates in ESMO East programs.

Dr. Seitkali's oncology practice covers solid tumors and lymphoma. In lung cancer, he prescribes osimertinib for EGFR-mutated NSCLC, alectinib for ALK-positive disease, pembrolizumab monotherapy for high PD-L1 NSCLC, and platinum-based doublets with PD-1 inhibitor combinations for lower PD-L1 expressors. For colorectal cancer, he manages FOLFOX/FOLFIRI with bevacizumab and anti-EGFR antibodies for RAS wild-type disease. For gastric cancer, he manages trastuzumab-containing regimens for HER2-positive disease and nivolumab combinations where accessible. He performs bone marrow biopsies for lymphoma staging and manages R-CHOP for diffuse large B-cell lymphoma.

Dr. Seitkali has published in the Kazakhstan Medical Journal and has contributed to ESMO East registry data. He participates in the Kazakhstan Society of Clinical Oncology activities and presents at the national oncology conference and ESMO Eastern Europe meetings. He collaborates with French oncology centers through the established academic exchange program.

The National Oncology Center Almaty serves Kazakhstan's domestic population and receives oncology referrals from Kyrgyzstan and other Central Asian countries. Dr. Seitkali consults in Kazakh, Russian, and English. Video consultations are available for oncology second opinions for patients from Central Asia.

Dr. Seitkali has been recognized by the Kazakhstan Society of Clinical Oncology for contributions to lung cancer treatment. He serves on the National Oncology Center tumor board and the Kazakhstan Ministry of Health oncology protocols committee.